Epithelial repair in COPD using patient-derived iPS cells

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers take bronchial samples by bronchoscopy and generate induced pluripotent stem (iPS) cells from participants, then use those cells before re-differentiation to test whether they can help repair airway epithelium in air-liquid interface (ALI) cultures. The project compares epithelial repair capacity and timing across three groups: COPD patients, smokers without COPD, and non-smoker controls. Investigators will examine whether grafted iPS-derived cells contribute to restored epithelial cell composition and function in the ALI model. The work aims to validate the ALI aggression model and determine feasibility of seeding iPS-derived epithelial cells for ex vivo repair.

Why it matters

Who can join: the full rules

General Inclusion Criteria

* Male and female participants aged 18 years or older.
* Participants with a bronchoscopy indication determined by a pulmonologist (e.g., follow-up exploration, nodule investigation, hemoptysis, cough, sputum production, recurrent bronchitis, or differential diagnosis).

Group 1 Inclusion Criteria: COPD

* Current or former smokers (≥10 pack-years).
* Diagnosed with COPD: FEV1/FVC \< 0.7 (confirmed by spirometry available in the medical file within the past year).

Group 2 Inclusion Criteria: Smokers without COPD (n=10)

* Current or former smokers (≥10 pack-years).
* No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC \> 0.7 and FEV1 \> 70% of predicted values) confirmed by spirometry within the past year.

Group 3 Inclusion Criteria: Non-smoker controls (n=10)

* Never-smokers or former smokers who quit more than 10 years ago (\<10 pack-years).
* No obstructive ventilatory disorder identified by clinical examination and/or (FEV1/FVC \> 0.7 and FEV1 \> 70% of predicted values) confirmed by spirometry within the past year.

Exclusion Criteria:

* Participant with extensive neoplastic disease.
* Participant with another progressive pulmonary condition (e.g., asthma, tuberculosis, interstitial lung disease, active or recent pulmonary infection).
* Participant consuming illicit drugs or alcohol.
* Individual deprived of liberty (by judicial or administrative decision, or under involuntary hospitalization).
* Individual currently enrolled in another research study with an ongoing exclusion period.
* Participant with recent psychiatric disorders (e.g., involuntary hospitalization, mental health conditions preventing informed consent, or requiring immediate medical intervention).
* Adult under legal protection (e.g., guardianship, curatorship, or judicial protection).
* Participant unable to provide informed consent.
* Participant not fluent in French and without a trusted person to assist with comprehension.
* Participant not affiliated with or covered by a social security system.
* Pregnant or breastfeeding women.
* Participant refusing to provide consent after being informed.
* Participant unable or incapable of expressing consent.

Where it's running

• University Hospital of Montpellier, Arnaud de Villeneuve Hospital
  Montpellier, Hérault, France Recruiting

Study contacts

• Principal investigator: Mathilde VOLPATO, MD — University Hospital, Montpellier
• Study coordinator: Isabelle VACHIER, PhD
• Email: isabelle.vachier@medbiomed.fr
• Phone: (0)467042020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.